AU3754285A - Creation of Inventions and Patents with Artificial Intelligence

AU3754285A – Fibrinolytically active enzyme conjugated to one human protein
– Google Patents

AU3754285A – Fibrinolytically active enzyme conjugated to one human protein
– Google Patents
Fibrinolytically active enzyme conjugated to one human protein

Info

Publication number
AU3754285A

AU3754285A
AU37542/85A
AU3754285A
AU3754285A
AU 3754285 A
AU3754285 A
AU 3754285A
AU 37542/85 A
AU37542/85 A
AU 37542/85A
AU 3754285 A
AU3754285 A
AU 3754285A
AU 3754285 A
AU3754285 A
AU 3754285A
Authority
AU
Australia
Prior art keywords
human protein
active enzyme
enzyme conjugated
fibrinolytically active
fibrinolytically
Prior art date
1984-01-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU37542/85A
Inventor
Harry Ferres
Andrew John Garman
Richard Anthony Godwin Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beecham Group PLC

Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1984-01-11
Filing date
1985-01-09
Publication date
1985-07-18

1985-01-09
Application filed by Beecham Group PLC
filed
Critical
Beecham Group PLC

1985-07-18
Publication of AU3754285A
publication
Critical
patent/AU3754285A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes

C12N9/14—Hydrolases (3)

C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)

C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue

C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

C12N9/6424—Serine endopeptidases (3.4.21)

C12N9/6456—Plasminogen activators

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient

A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates

A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent

A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment

A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent

A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates

A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin

A61K47/6815—Enzymes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof

C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC

Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Y10S530/81—Carrier – bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

AU37542/85A
1984-01-11
1985-01-09
Fibrinolytically active enzyme conjugated to one human protein

Abandoned

AU3754285A
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

GB848400653A

GB8400653D0
(en)

1984-01-11
1984-01-11
Conjugates

GB8400653

1984-01-11

Publications (1)

Publication Number
Publication Date

AU3754285A
true

AU3754285A
(en)

1985-07-18

Family
ID=10554819
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU37542/85A
Abandoned

AU3754285A
(en)

1984-01-11
1985-01-09
Fibrinolytically active enzyme conjugated to one human protein

Country Status (8)

Country
Link

US
(1)

US4673573A
(en)

EP
(1)

EP0152736A3
(en)

JP
(1)

JPS60174724A
(en)

AU
(1)

AU3754285A
(en)

ES
(1)

ES539432A0
(en)

GB
(1)

GB8400653D0
(en)

GR
(1)

GR850067B
(en)

ZA
(1)

ZA85206B
(en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB8334499D0
(en)

1983-12-24
1984-02-01
Beecham Group Plc
Derivatives

US5256413A
(en)

1985-01-08
1993-10-26
The General Hospital Corporation
Method and use for site-specific activation of substances

NZ217844A
(en)

1985-10-11
1989-10-27
Sumitomo Pharma
A sustained release pharmaceutical composition containing silicone elastomer and an albumin

US5089406A
(en)

1987-01-07
1992-02-18
Allied-Signal Inc.
Method of producing a gene cassette coding for polypeptides with repeating amino acid sequences

GB8705377D0
(en)

1987-03-07
1987-04-08
Beecham Group Plc
Compounds

GB8707369D0
(en)

1987-03-27
1987-04-29
Beecham Group Plc
Enzyme derivatives

US5009888A
(en)

1987-04-13
1991-04-23
Genzyme Corporation
Therapeutic enzyme-antibody complexes

GB8711957D0
(en)

1987-05-20
1987-06-24
Beecham Group Plc
Compounds

GB8715302D0
(en)

1987-06-30
1987-08-05
Ordidge R J
Nmr spectroscopy

AU615919B2
(en)

1987-07-01
1991-10-17
Beecham Group Plc
Hybrid plasminogen activators

US5302390A
(en)

1987-07-01
1994-04-12
Beecham Group Plc
Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment

US5582862A
(en)

1988-04-04
1996-12-10
General Hospital Corporation
Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin

US5372812A
(en)

1988-04-04
1994-12-13
The General Hospital Corporation
Composition and method for acceleration of clot lysis

US5225540A
(en)

1988-04-26
1993-07-06
Du Pont Merck Pharmaceutical Company
Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life

US5609869A
(en)

1988-08-19
1997-03-11
The General Hospital Corporation
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use

US5811265A
(en)

1988-08-19
1998-09-22
The General Hospital Corporation
Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use

US6007817A
(en)

1988-10-11
1999-12-28
University Of Southern California
Vasopermeability enhancing immunoconjugates

EP0395918A3
(en)

1989-04-13
1991-10-23
Vascular Laboratory, Inc.
Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin

CA1335361C
(en)

1989-05-24
1995-04-25
Andrei Z. Budzynski
Thrombus-targeted complexes of plasminogen activator and fibrin fragments

US5169934A
(en)

1990-05-14
1992-12-08
Anergen, Inc.
Intracellularly cleavable compounds

US5632986A
(en)

1991-05-09
1997-05-27
The University Of Washington
Phospholipid-targeted thrombolytic agents

CA2062240A1
(en)

1991-06-07
1992-12-08
Susan J. Danielson
Labeled hydantoin derivatives for immunoassays

JP2606643B2
(en)

1992-04-01
1997-05-07
日東紡績株式会社

Benzoic acid amidinophenyl ester derivative

ES2066733B1
(en)

1993-06-30
1995-11-01
Antibioticos Farma S A

COMPLEX CONSISTING OF AN ACTIVATOR OF PLASMINOGEN AND SERUM ALBUMIN AND PROCEDURE TO PREPARE IT.

US5607841A
(en)

1994-06-20
1997-03-04
Lipinski; Boguslaw
Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen

GB9614871D0
(en)

1996-07-15
1996-09-04
Smithkline Beecham Plc
Compounds

WO1998012334A2
(en)

1996-09-20
1998-03-26
The General Hospital Corporation
Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin

DE69731985T2
(en)

1996-10-21
2005-12-29
Quadrant Drug Delivery Ltd., Ruddington

BLANK SPARE PARTS AND SUITABLE CONJUGATION MANUFACTURING PROCESS

GB0111420D0
(en)

2001-05-10
2001-07-04
Biovector Solutions Ltd
Soluble polymer systems for drug delivery

US7541159B2
(en)

2004-04-14
2009-06-02
The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration
Molecular-specific urokinase antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US4464468A
(en)

1968-03-29
1984-08-07
Agence Nationale De Valorisation De La Recherche (Anvar)
Immobilization of active protein by cross-linking to inactive protein

US4082612A
(en)

1976-09-24
1978-04-04
Michael Reese Research Foundation
Plasminogen activator complex

US4134792A
(en)

1976-12-06
1979-01-16
Miles Laboratories, Inc.
Specific binding assay with an enzyme modulator as a labeling substance

SE427505B
(en)

1977-03-04
1983-04-11
Pharmacia Diagnostics Ab

REAGENT USE FOR IMMUNKEMIC DETERMINATION METHODS

JPS5411219A
(en)

1977-06-25
1979-01-27
Green Cross Corp:The
Thrombolytic agent and its preparation

EP0000938B1
(en)

1977-08-22
1984-10-17
National Research Development Corporation
Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them

NZ191320A
(en)

1978-09-07
1982-09-14
Beecham Group Ltd
In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

US4305926A
(en)

1979-09-13
1981-12-15
Johannes Everse
Immobilization of Streptokinase

DE3065190D1
(en)

1979-11-05
1983-11-10
Beecham Group Plc
Enzyme derivatives, and their preparation

DE3361610D1
(en)

1982-04-07
1986-02-06
Beecham Group Plc
Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them

US4530900A
(en)

1982-09-13
1985-07-23
Seragen Diagnostics Inc.
Soluble insoluble polymers in enzymeimmunoassay

EP0109653A3
(en)

1982-11-17
1986-01-29
Otsuka Pharmaceutical Co., Ltd.
Process for preparing urokinase complex

SU1128601A1
(en)

1983-05-10
1985-07-15
Всесоюзный кардиологический научный центр АМН СССР
Urocinase immobilized on fibrinogen

JPS60136520A
(en)

1983-12-23
1985-07-20
Otsuka Pharmaceut Co Ltd
Fibrin-adsorbing urokinase complex

GB8334499D0
(en)

1983-12-24
1984-02-01
Beecham Group Plc
Derivatives

1984

1984-01-11
GB
GB848400653A
patent/GB8400653D0/en
active
Pending

1985

1985-01-04
EP
EP85100084A
patent/EP0152736A3/en
not_active
Withdrawn

1985-01-09
ZA
ZA85206A
patent/ZA85206B/en
unknown

1985-01-09
AU
AU37542/85A
patent/AU3754285A/en
not_active
Abandoned

1985-01-09
US
US06/689,846
patent/US4673573A/en
not_active
Expired – Fee Related

1985-01-09
ES
ES539432A
patent/ES539432A0/en
active
Granted

1985-01-10
JP
JP60001538A
patent/JPS60174724A/en
active
Pending

1985-01-10
GR
GR850067A
patent/GR850067B/el
unknown

Also Published As

Publication number
Publication date

ES8602118A1
(en)

1985-11-01

ES539432A0
(en)

1985-11-01

GR850067B
(en)

1985-05-16

US4673573A
(en)

1987-06-16

GB8400653D0
(en)

1984-02-15

EP0152736A3
(en)

1986-12-10

EP0152736A2
(en)

1985-08-28

JPS60174724A
(en)

1985-09-09

ZA85206B
(en)

1986-04-30

Contact information